Salvat Laboratories enters in the Hong Kong market with its first otic medication

/in , , /by
  • Salvat has an agreement with Lee’s Pharmaceutical to distribute the otic treatment Cetraxal Plus in China, Hong Kong and Taiwan.
  • The product has been available in the Spanish market for twenty years and is exported to more than 50 countries.
  • Cetraxal Plus is the only otic treatment in the world that comes in single-dose vials for acute otitis externa and otitis media with tympanostomy tubes.
  • With this project, Salvat reinforces its commitment to the Asian market, where it is already present in markets such as Korea, Singapore and Vietnam.

Salvat Laboratories (“Salvat”) and Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”) (SEHK Stock Code:0950) have launched Salvat Cetraxal Plus otic treatment in Hong Kong, marking the first time the laboratory has operated in the Asian country.

Lee’s Pharmaceutical acquired the license rights from Salvat to sell Cetraxal Plus in China, Taiwan and Hong Kong in single-dose vials. Following clinical trials and official approvals the treatment has started to be marketed this October in Hong Kong and is scheduled to be marketed in China and Taiwan next year. “The Asian market, and especially China, are strategic markets for Salvat due to their growth potential and high demand for health and self-care products”, explains Alberto Bueno, CEO of Salvat.

Clinical trials in China

In China, the Phase III clinical trial for the drug is currently underway and most of the necessary patients have already been recruited from 44 centers across the country. The study is led by researchers from Fudan University and is scheduled to be completed before the end of 2021. The final phase will be the regulatory process for the product’s approval in the country.

This clinical trial is the prerequisite for obtaining authorization from the Chinese National Medical Products Administration to market the drug, in their country.

The world’ s first treatment in single-dose vials for both otic conditions

Cetraxal Plus is the only otic treatment in the world for acute otitis externa and otitis media with tympanostomy tubes that comes in single-dose or single-use vials. This presents several benefits over multidose formats, as it facilitates correct administration with the exact amount of product and maintains the sterility of the treatment. “At Salvat, we are committed to technology and innovation in drug development and the single-dose formats allow us to offer increasingly advanced solutions adapted to the needs of the market. We manufacture them in the production lines owned by the Salvat Group: “Salvat (Barcelona), Pharmaloop (Alcalá de Henares, Madrid) and Tamarac (Florida, USA)” explains the CEO of Salvat, Alberto Bueno.

With almost twenty years on the market, Cetraxal Plus has become one of Salvat’s key products. It is a treatment for acute otitis externa and otitis media with tympanostomy tubes that combines an antibiotic and a corticosteroid. Every year more than 1,500,000 units are sold in Spain and more than 3,000,000 are exported to 50 countries around the world.